{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:54Z","timestamp":1791305934474,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010334","name":"Royal College of General Practitioners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ajog.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T10:16:13Z","timestamp":1486548973000},"page":"580.e1-580.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":230,"title":["Lifetime cancer risk and combined oral contraceptives: the\u00a0Royal College of General Practitioners\u2019 Oral Contraception Study"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-5229","authenticated-orcid":false,"given":"Lisa","family":"Iversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Sivasubramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hannaford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.02.002_bib1","series-title":"Sexual chemistry: a history of the contraceptive pill","author":"Marks","year":"2001"},{"key":"10.1016\/j.ajog.2017.02.002_bib2","series-title":"World contraceptive patterns 2013","year":"2013"},{"key":"10.1016\/j.ajog.2017.02.002_bib3","unstructured":"International Agency for Research on Cancer & World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http:\/\/globocan.iarc.fr\/Pages\/age-specific_table_sel.aspx. Accessed May 6,\u00a02015."},{"key":"10.1016\/j.ajog.2017.02.002_bib4","series-title":"IARC Monographs on the Evaluation and Carcinogenic Risks to Man. Volume 100A Pharmaceuticals. A review of human carcinogens","first-page":"283","year":"2012"},{"key":"10.1016\/j.ajog.2017.02.002_bib5","series-title":"Oral contraceptives and health","year":"1974"},{"key":"10.1016\/j.ajog.2017.02.002_bib6","series-title":"Classification of occupations, 1966","year":"1966"},{"key":"10.1016\/j.ajog.2017.02.002_bib7","series-title":"International classification of disease, injuries and causes of death, 8th revision","year":"1967"},{"key":"10.1016\/j.ajog.2017.02.002_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","article-title":"Cancer risk among oral contraceptive users: cohort data from the Royal College of General Practitioner\u2019s Oral Contraception Study","volume":"335","author":"Hannaford","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2017.02.002_bib9","series-title":"Evidence-guided prescribing of the pill","first-page":"327","article-title":"Mortality in relation to method of follow-up in the Royal College of General Practitioners\u2019 Oral Contraception Study","author":"Beral","year":"1996"},{"key":"10.1016\/j.ajog.2017.02.002_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bmj.318.7176.96","article-title":"Mortality associated with oral contraceptives: 25 year follow of cohort of 46,000 women from the Royal College of General Practitioners\u2019 Oral Contraception Study","volume":"318","author":"Beral","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2017.02.002_bib11","unstructured":"Cancer Research UK. Female age-specific incidence rates of all cancers excluding non-melanoma skin cancer C00-97 Excl. C44): 2011-2013. Available at: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/age#heading-Zero. Accessed August 3,\u00a02016."},{"key":"10.1016\/j.ajog.2017.02.002_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jech.52.7.420","article-title":"Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal College of General Practitioners\u2019 Oral Contraception Study in the UK","volume":"52","author":"Owen-Smith","year":"1998","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.ajog.2017.02.002_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1471-0528.1997.tb11456.x","article-title":"Prevalence and characteristics associated with use of hormone replacement therapy in Britain","volume":"104","author":"Moorhead","year":"1997","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.02.002_bib14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.02.002_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.02.002_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Tamoxifen and uterine cancer. Committee Opinion No. 601","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.002_bib17","first-page":"277","article-title":"Use of oral contraceptives and endometrial cancer risk (Sweden)","volume":"10","author":"Weiderpass","year":"1999","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ajog.2017.02.002_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/aje\/152.3.233","article-title":"Risk of ovarian cancer in relation to estrogen and progestin dose and use of characteristics of oral contraceptives","volume":"152","author":"Ness","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2017.02.002_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T","article-title":"Low-dose oral contraceptives: protective effect on ovarian cancer risk","volume":"95","author":"Royar","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2017.02.002_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.02.002_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","article-title":"Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2017.02.002_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.contraception.2011.08.007","article-title":"Oral contraceptive formulation and risk of breast cancer","volume":"85","author":"Marchbanks","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2017.02.002_bib23","first-page":"4078","article-title":"Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age","volume":"74","author":"Beaber","year":"2014","journal-title":"Prev Epidemiol"},{"key":"10.1016\/j.ajog.2017.02.002_bib24","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of nonoral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2017.02.002_bib25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.02.002_bib26","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2017.02.002_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2013.08.008","article-title":"Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study","volume":"88","author":"Vessey","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2017.02.002_bib28","doi-asserted-by":"crossref","first-page":"g6356","DOI":"10.1136\/bmj.g6356","article-title":"Oral contraceptive use and mortality after 36 years of follow-up in the Nurse\u2019 Health Study: prospective cohort study","volume":"349","author":"Charlton","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2017.02.002_bib29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","volume":"370","year":"2007","journal-title":"Lancet"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817301795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817301795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:33:30Z","timestamp":1762079610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817301795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0002937817301795"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.02.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727321644.793547607","asserted-by":"object"}]},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifetime cancer risk and combined oral contraceptives: the\u00a0Royal College of General Practitioners\u2019 Oral Contraception Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}